Open-label phase 3 study of diclofenac conjugated to hyaluronate (diclofenac etalhyaluronate: ONO-5704/SI-613) for treatment of osteoarthritis: 1-year follow-up

Table 5 Subgroup analyses in the full analysis set

	Baseline Mean ± SD	Week 2 Mean ± SD	Week 12 Mean ± SD	Week 24 Mean ± SD	Week 52 Mean ± SD
Patients with knee OA or other OA
Knee OA (n)	126	126	122	121	120
Pain score	6.0 ± 1.1	4.9 ± 2.0	4.5 ± 2.2	4.0 ± 2.4	3.1 ± 2.4
WOMAC score (mm)
Pain	40.9 ± 18.7	33.1 ± 21.2	29.3 ± 22.3	26.7 ± 22.4	21.7 ± 22.1
Stiffness	39.9 ± 25.9	32.2 ± 23.6	30.2 ± 24.5	28.2 ± 24.7	21.8 ± 22.6
Function	40.5 ± 21.7	35.0 ± 23.0	29.4 ± 22.7	27.2 ± 23.7	22.0 ± 22.8
Total	40.5 ± 20.2	34.4 ± 22.0	29.5 ± 22.3	27.2 ± 23.1	21.9 ± 22.3
Other OA (n)	40	40	40	37	37
Pain score	5.7 ± 1.3	4.7 ± 1.9	3.9 ± 2.2	3.6 ± 2.0	2.9 ± 2.3
Patients with or without analgesics for OA
Use^a (n)	135	135	132	129	128
Pain score	5.9 ± 1.2	4.9 ± 1.9	4.3 ± 2.1	4.0 ± 2.2	3.2 ± 2.3
Not used^b (n)	31	31	30	29	29
Pain score	5.7 ± 1.2	4.7 ± 2.2	4.3 ± 2.4	3.7 ± 2.5	2.4 ± 2.4

n number of patients in the subgroup, OA osteoarthritis, WOMAC Western Ontario and McMaster University Osteoarthritis 3.1 index
^aPatients who used analgesics for OA
^bPatients who did not use analgesics for OA

ISSN: 1471-2474